Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Cecchini

Showing results (101-110 of 145) with videos related to

Pageof 15
Sort By:
Cancer|May 10, 2012
Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01Kelley M Kidwell, Greg Yothers, Patricia A Ganz, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 13, 2012
Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR)Reena S Cecchini, Joseph P Costantino, Jane A Cauley, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 10, 2012
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trialsReena S Cecchini, Joseph P Costantino, Jane A Cauley, et al.
Breast Cancer Research and Treatment|February 28, 2008
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trialSandra M Swain, Stephanie R Land, Marcie W Ritter, et al.
American Journal of Obstetrics and Gynecology|August 30, 2011
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)Carolyn D Runowicz, Joseph P Costantino, D Lawrence Wickerham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2021
Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35N Lynn Henry, Sungjin Kim, Ron D Hays, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Cancer screening in the European UnionA del Moral Aldaz, M Aupee, S Batal-Steil, et al.
The Journal of Head Trauma Rehabilitation|January 7, 2017
Military-Civilian Collaborations for mTBI Rehabilitation Research in an Active Duty Population: Lessons Learned From the Assessment of Military Multitasking Performance ProjectKaren L McCulloch, Amy S Cecchini, Mary V Radomski, et al.
Plos One|January 6, 2017
Further Development of the Assessment of Military Multitasking Performance: Iterative Reliability TestingMargaret M Weightman, Karen L McCulloch, Mary V Radomski, et al.
NPJ Breast Cancer|November 19, 2022
Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30N Lynn Henry, Sungjin Kim, Ron D Hays, et al.
Pageof 15

Showing results (101-110 of 145) with videos related to

Sort By:
Pageof 15
Cancer|May 10, 2012
Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01Kelley M Kidwell, Greg Yothers, Patricia A Ganz, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 13, 2012
Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR)Reena S Cecchini, Joseph P Costantino, Jane A Cauley, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 10, 2012
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trialsReena S Cecchini, Joseph P Costantino, Jane A Cauley, et al.
Breast Cancer Research and Treatment|February 28, 2008
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trialSandra M Swain, Stephanie R Land, Marcie W Ritter, et al.
American Journal of Obstetrics and Gynecology|August 30, 2011
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)Carolyn D Runowicz, Joseph P Costantino, D Lawrence Wickerham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2021
Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35N Lynn Henry, Sungjin Kim, Ron D Hays, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Cancer screening in the European UnionA del Moral Aldaz, M Aupee, S Batal-Steil, et al.
The Journal of Head Trauma Rehabilitation|January 7, 2017
Military-Civilian Collaborations for mTBI Rehabilitation Research in an Active Duty Population: Lessons Learned From the Assessment of Military Multitasking Performance ProjectKaren L McCulloch, Amy S Cecchini, Mary V Radomski, et al.
Plos One|January 6, 2017
Further Development of the Assessment of Military Multitasking Performance: Iterative Reliability TestingMargaret M Weightman, Karen L McCulloch, Mary V Radomski, et al.
NPJ Breast Cancer|November 19, 2022
Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30N Lynn Henry, Sungjin Kim, Ron D Hays, et al.
Pageof 15